Sanofi's Wayrilz receives EU approval for the treatment of IPT

The European Commission has approved Wayrilz, a BTK inhibitor developed by Sanofi, for the treatment of immune thrombocytopenia (ITP) in refractory adults. This decision is based on the phase 3 LUNA 3 study, which demonstrated a rapid and sustained platelet response. ITP, a rare disease causing a drop in platelets and bleeding, severely impacts patients' quality of life.

Wayrilz, already approved in the United States and the United Arab Emirates, is under review in China and Japan. It has also received several orphan drug designations. Its most common side effects include diarrhea and nausea. In addition, it is being studied for other rare diseases such as autoimmune hemolytic anemia. Sanofi's approach highlights its ability to develop innovative treatments for rare diseases.